Pulmonary Sarcoidosis following Etanercept Treatment

License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Tumour necrosis factor (TNF) is an important cytokine involved in the pathology of a number of inflammatory conditions, and thus blockade with anti-TNF therapies is becoming the cornerstone in managing such diseases. With increasing use, evidence is collected for the association of sarcoid-like granulomatous disease developing after the initiation of anti-TNF-α therapy, with disease reversal after discontinuation. 1